News

Jun 16, 2021 Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes

Jun 11, 2021 Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

Jun 09, 2021 Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

Jun 07, 2021 Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021

May 14, 2021 Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

May 14, 2021 Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

May 11, 2021 Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific Time

Apr 30, 2021 Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health's Cancer Progress Virtual Conference on May 6, 2021

Apr 08, 2021 Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access Pathway

Mar 31, 2021 Headline test 2

<< < > >>